Literature DB >> 26022657

Functional characterization of 20 allelic variants of CYP1A2.

Miyabi Ito1, Yuki Katono1, Akifumi Oda2, Noriyasu Hirasawa1, Masahiro Hiratsuka3.   

Abstract

Genetic variations in cytochrome P450 1A2 (CYP1A2) are associated with interindividual variability in the metabolism and efficacy of many medications. Twenty CYP1A2 variants harboring amino acid substitutions were analyzed for functional changes in enzymatic activity. Recombinant CYP1A2 variant proteins were heterologously expressed in COS-7 cells. Enzyme kinetic analyses were performed with two representative CYP1A2 substrates, phenacetin and 7-ethoxyresorufin. Among the 20 CYP1A2 allelic variants, CYP1A2*4, CYP1A2*6, CYP1A2*8, CYP1A2*15, CYP1A2*16, and CYP1A2*21 were inactive toward both substrates. CYP1A2*11 showed markedly reduced activity, but the changes in Km were different between the substrates. CYP1A2*14 and CYP1A2*20 exhibited increased activity compared to the wild-type enzyme, CYP1A2*1. This comprehensive in vitro assessment provided insight into the specific metabolic activities of CYP1A2 proteins encoded by variant alleles, which may to be valuable when interpreting the results of in vivo studies.
Copyright © 2015 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  7-Ethoxyresorufin; CYP1A2; Cytochrome P450; Genetic polymorphism; Phenacetin

Mesh:

Substances:

Year:  2015        PMID: 26022657     DOI: 10.1016/j.dmpk.2015.03.001

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  5 in total

1.  Clinical and genetic influencing factors on clozapine pharmacokinetics in Tunisian schizophrenic patients.

Authors:  Helmi Ammar; Zohra Chadli; Ahmed Mhalla; Sabria Khouadja; Ibtissem Hannachi; Mohammed Alshaikheid; Ahlem Slama; Nadia Ben Fredj; Najeh Ben Fadhel; Haifa Ben Romdhane; Amel Chaabane; Naceur A Boughattas; Lotfi Gaha; Lazhar Zarrouk; Karim Aouam
Journal:  Pharmacogenomics J       Date:  2021-03-17       Impact factor: 3.550

2.  In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17β-dihydroexemestane.

Authors:  Amity Peterson; Zuping Xia; Gang Chen; Philip Lazarus
Journal:  Pharmacol Res Perspect       Date:  2017-04-27

3.  In silico screening and analysis of nonsynonymous SNPs in human CYP1A2 to assess possible associations with pathogenicity and cancer susceptibility.

Authors:  Leila Navapour; Navid Mogharrab
Journal:  Sci Rep       Date:  2021-03-02       Impact factor: 4.379

Review 4.  Structure-Based Drug Design for Cytochrome P450 Family 1 Inhibitors.

Authors:  Zbigniew Dutkiewicz; Renata Mikstacka
Journal:  Bioinorg Chem Appl       Date:  2018-07-25       Impact factor: 7.778

5.  Heterologous expression of high-activity cytochrome P450 in mammalian cells.

Authors:  Masaki Kumondai; Eiji Hishinuma; Evelyn Marie Gutiérrez Rico; Akio Ito; Yuya Nakanishi; Daisuke Saigusa; Noriyasu Hirasawa; Masahiro Hiratsuka
Journal:  Sci Rep       Date:  2020-08-25       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.